Maralixibat reduces pruritus, xanthoma in children with Alagille syndrome

BOSTON — Maralixibat demonstrated durable control of serum bactericidal antibody, pruritus, and xanthoma in children with Alagille syndrome, according to data from the ICONIC study presented at The Liver Meeting 2019.“Alagille syndrome is a rare genetic, multisystem, development disease,” Emmanuel M. Gonzales, MD, from the University Hospitals of Paris-Sud Bicêtre in France, said during his presentation. “Alagille syndrome may involve many different organs and is associated with growth deficit. Currently, there are no approved pharmacological treatments for thisRead More

Share on facebook
Share on twitter
Share on linkedin